Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. [PDF]
J Clin OncolLarotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a ...
Mascarenhas L +23 more
europepmc +3 more sources
Drug delivery system for the extended-release of larotrectinib based on a biocompatible Fe-based metal-organic framework: synthesis, characterization, in vitro release properties and antitumor evaluation [PDF]
Frontiers in Bioengineering and Biotechnology, 2023 Larotrectinib (Lar) is an orally administered tropomyosin receptor kinase (Trk) inhibitor with broad-spectrum antitumor activity that is available in clinical dosage forms as capsules and oral solutions.
Lu Gan +5 more
doaj +2 more sources
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib [PDF]
BMC Cancer, 2022 Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors.
James C. H. Yang +15 more
doaj +2 more sources
A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report [PDF]
BMC Pulmonary Medicine, 2021 Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor.
Lei Zhang +4 more
doaj +2 more sources
Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases [PDF]
European Journal of Pediatric Surgery Reports, 2022 Congenital infantile fibrosarcoma (CIF) is a rare tumor in children that occurs in the first years of life. It usually arises in the extremities but some cases affect the trunk, neck, abdomen, or retroperitoneum. Surgical resection has been traditionally
Lucas Moratilla Lapeña +9 more
doaj +2 more sources
Journal of Applied Pharmaceutical ResearchBackground: Larotrectinib, a selective TRK inhibitor, received FDA approval on April 10, 2025, for treating solid tumors with NTRK gene fusions. Despite its therapeutic significance, no RP-HPLC method using a Quality-by-Design (QbD) framework has been ...
Syamala P. N. S, Sreedevi Adikay
doaj +2 more sources
NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report [PDF]
Frontiers in PharmacologyIntroductionA 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.Patient concernsThe patient experienced chest pain for 2 ...
Jielin Li +5 more
doaj +2 more sources
Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
Case Reports in Oncology, 2023 In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these ...
Lorenz Frehner +4 more
doaj +2 more sources
Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma [PDF]
Frontiers in OncologyOncotherapy can shape intestinal microbiota, which, in turn, may influence therapy effectiveness. Furthermore, microbiome signatures during treatments can be leveraged for the development of personalised therapeutic protocols in cancer treatment based on
Luigia Turco +23 more
doaj +2 more sources